 BOSTON, June 30, 2022 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer, will take part in a fireside chat during the conference. Ron and Simon Harford, Chief Financial Officer, will also host meetings during the conference. 